Management of Bradycardia in Biventricular Heart Failure

Initial Assessment and Reversible Causes

The American Heart Association recommends assessing for signs of poor perfusion, such as acute altered mental status, ischemic chest discomfort, acute heart failure exacerbation, hypotension, or other signs of shock in patients with biventricular heart failure and bradycardia 1
Evaluating oxygenation status is crucial, as hypoxemia is a common reversible cause of bradycardia, and assessing work of breathing and pulse oximetry is necessary 1
Obtaining a 12-lead ECG is essential to identify the specific bradyarrhythmia, such as sinus bradycardia or AV block 1
Reviewing all medications that may contribute to bradycardia, including beta-blockers, digoxin, amiodarone, and ivabradine, is vital 2, 3

The European Society of Cardiology recommends reducing or discontinuing ivabradine if present, and reducing beta-blocker dose by 50% rather than complete discontinuation in patients with biventricular heart failure and bradycardia 2, 3, 6
Reducing or discontinuing other rate-lowering drugs, such as digoxin and amiodarone, before stopping beta-blockers entirely is recommended 2, 6
Symptomatic bradycardia or hypotension is an absolute contraindication to beta-blocker therapy, but asymptomatic bradycardia alone may not require intervention if the patient is otherwise stable 1, 2, 6

The European Heart Rhythm Association recommends considering cardiac resynchronization therapy (CRT) in patients with biventricular failure and bradycardia, particularly if QRS duration is >120 ms or LVEF is <35% 8
CRT can dramatically improve hemodynamics in critical heart failure with bradycardia, and may allow reduction in inotropic support 8
Biventricular pace-and-ablate strategy may be beneficial in patients with atrial fibrillation, heart failure, and drug-induced bradycardia 8

The American College of Cardiology recommends maintaining a patent airway and assisting breathing as necessary, providing oxygen if hypoxemic, and establishing IV access and continuous cardiac monitoring in patients with symptomatic bradycardia 1
Considering atropine (0.5 mg IV, may repeat) for symptomatic bradycardia, and preparing for transcutaneous or transvenous pacing if medications fail is crucial 1

The European Society of Cardiology recommends prioritizing ACE inhibitors/ARBs/ARNIs and SGLT2 inhibitors, which do not cause bradycardia, and using the lowest effective dose of beta-blocker that controls symptoms without causing symptomatic bradycardia 3, 4
Considering switching from carvedilol to metoprolol or bisoprolol if bradycardia is problematic, as carvedilol has additional alpha-blocking effects, and device therapy (CRT) may allow optimization of medical therapy by eliminating drug-induced bradycardia as a limiting factor 3, 4